BD (Becton, Dickinson and Company) announced on May 13, 2025, the global commercial launch of a new cell analyzer, touted as the world's first to feature breakthrough spectral and real-time cell imaging technologies. This innovation is designed to enable researchers to uncover deeper insights and dynamics from cells that were previously invisible in flow cytometry experiments.
The new cell analyzer aims to provide increased ease and throughput for a wider range of applications. This technological advancement is expected to enhance research capabilities across various scientific fields, including immunology and cancer research.
This launch reinforces BD's commitment to innovation and its strategy to deliver solutions that leverage significant shifts in technology. The new platform is positioned to drive growth by offering differentiated capabilities to its customers in the life sciences sector.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.